Table 1.
Patient characteristics at baseline and 1-year follow-up.
| Characteristics | All Patients (n = 54) | |
|---|---|---|
| Baseline | One-Year Follow-Up | |
| Clinical Characteristics | ||
| Age (years) | 61 (48–73) | - |
| Duration of asthma (years) | 18 (4–31) | - |
| Asthma onset ≥ 18 years, n (%) | 42 (77.8) | - |
| Sex: male, n (%) | 28 (51.9) | - |
| Body mass index (kg/m2) | 23.6 (21.2–26.8) | - |
| Obesity, n (%) (BMI ≥ 30 kg/m2) | 20 (37.0) | |
| Former smoker, n (%) | 22 (40.7) | - |
| Type 2 biomarker | ||
| Blood eosinophils (/μL) | 501 (320–938) | 61 (0–219) * |
| FeNO, (ppb) | 64 (37–123) | 32 (20–60) * |
| Atopy | 37 (68.5) | - |
| Total serum IgE (IU/mL) | 256 (76–661) | - |
| Comorbidity | ||
| Allergic rhinitis, n (%) | 34 (63.0) | - |
| Chronic rhinosinusitis, n (%) | 37 (68.5) | - |
| Uncontrolled features | ||
| Exacerbation in the previous year, 0/1/≥2, n (%) | 22/11/21(40.7/20.4/38.9) | 45/7/2 (83.3/13.0/3.7) * |
| ACQ | 1.6 (1.0–2.4) | 0.7 (0.4–1.0) * |
| FEV1 % predicted (%) | 77.0 (51.8–91.5) | 90.8 (73.3–99.0) * |
| Treatment | ||
| Use of ICS/LABA, n (%) | 54 (100.0) | - |
| Use of LAMA, n (%) | 33 (61.1) | - |
| Use of LTRA, n (%) | 29 (53.7) | - |
| Use of maintenance OCS, n (%) | 20 (37.0) | 7 (13.0) * |
| Maintenance OCS dose † (mg/day) | 6.0 (5.0–10.0) | 0.0 (0.0–2.9) * |
| Type of biologics, Oma/Mep/Ben/Dup/Switch, n (%) | 6/4/18/13/13 (11.1/7.4/33.3/24.1/24.1) | - |
| Number of each remission criterion achieved, 0/1/2/3/4/5, n (%) |
4/14/23/11/2/0 (7.4/25.9/42.6/20.4/3.7/0.0) |
0/7/10/3/17/17 (0.0/13.0/18.5/5.6/31.5/31.5) * |
Data are presented as the median (interquartile range) or n (%). † Maintenance OCS dose is provided as prednisone-equivalent for patients on chronic OCS therapy. * p < 0.05 (baseline vs. 1-year follow-up). LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; Oma, omalizumab; Mep, mepolizumab; Ben, benralizumab; Dup, dupilumab; Switch, switched to biologic from other biologics; ACQ, asthma control questionnaire.